ISSN: 2517-7370
Cancer is generally referred to as a disease that involves abnormal growth of cells that have the potential to spread in different parts of the body. The disease may be curable if detected in early stages. It is most prevalent disease ...
Explore the journal aims, scope and subject coverage before submission.
View editorial leadership and board information for this journal.
Browse current research articles and article updates from this journal.
Open Access publishing information is available for authors and readers.
Robert J. Amato is a Professor in the Department of Internal Medicine and Director of the Division of Oncology at McGovern Medical School, The University of Texas Health Science Center at Houston, and the Memorial Hermann Cancer Center.
He received his D.O. from The University of North Texas in Fort Worth, Texas, in 1983. He serves as an editorial board member and reviewer for numerous journals and has had more than 300 publications over the course of his career.
Dr. Amato is one of the world’s leading experts in the treatment of genitourinary cancer. Early in his career, his research helped make testicular cancer a highly treatable disease. His current clinical research focuses on molecular-targeted therapeutics to halt the progression of metastatic kidney and prostate cancers, the further development of immunotherapies with a primary focus on vaccine and immune therapy, and the development of more effective treatments for bladder cancer. He is also involved in a number of translational research projects seeking insight into the molecular alterations associated with disease progression and resistance adaptation, as well as biomarker discovery.
Discover peer-reviewed open access journals across diverse disciplines.
